NEW YORK – Hitachi High-Tech of Japan and Gencurix of South Korea said Wednesday that they have inked a strategic partnership aimed at developing a cancer molecular diagnostics service, initially for the Japanese market.
The companies said they have already conducted an initial feasibility study that was completed in June. The next step will be to commercialize their planned testing services.
Hitachi High-Tech said it currently already sells various types of in vitro diagnostic equipment including DNA sequencers. The collaboration with Gencurix is part of its "growth strategy of strengthening this molecular diagnostics business."
Gencurix, which was established in 2011 in Seoul, provides molecular diagnostic testing across the cancer care process including early detection, prognostic testing, companion diagnostics, and recurrence monitoring.
The companies did not detail the tests they plan to launch but described the partnership as promoting personalized medicine and employing "digital technology."